COPD Special Report: The Year in Review

Reduced exacerbations, improved lung function, increased QoL, and less use of systemic corticosteroids underscore dupilumab's effects against type 2 inflammation.

Despite a 20-pack year smoking history and frequent respiratory exacerbations, spirometry is preserved in this group of heavy smokers.

Patients with diabetes had a 35% higher risk of COPD compared with those without diabetes, according to new research.

Results of a new study offer additional support for clinical guidelines to favor one therapy over another, authors suggest.

At the 2023 American Thoracic Society International Conference a symposium focused on common comorbidities seen with COPD, their management, and research needs.

Findings of the BOREAS trial of patients with COPD and type 2 inflammation make dupilumab the first biologic to significantly reduce exacerbations by 30% vs placebo.